MET and cancer: In the first case, mutations occur in the extracellular SEMA domain, likely affecting the ligand–receptor interaction or the ability of MET to dimerize, and have been detected in lung, gastric, and breast cancer [48], as well as in cancers of unknown primary (CUPs) [52].